Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
98.16%
Operating Margin
50.91%
Net Margin
32.78%
Efficiency Metrics
Revenue per Expense Ratio
2.12
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.51%
EPS
0.8800000000
Balance Sheet Analysis
Current Ratio
0.04
Cash Ratio
0.04
Working Capital
$-4.86B
Debt to Equity
8.79
Debt to Assets
87.06%
Equity Ratio
9.91%
Cash Flow Analysis
Operating Cash Flow Ratio
44.30%
Free Cash Flow Ratio
44.28%
CapEx to Revenue
0.01%
Dividends Paid
$149.27M
Stock Buybacks
$12.35M
Total Shareholder Returns
$161.62M
Cash Position Change
3.91%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 6.46%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
494.48%
Net Income
1,258.98%
EPS
833.33%
Operating Income
14.07%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
124.64%
Operating Cash Flow
-666.60%
Free Cash Flow
-6,859.59%
Balance Sheet Health
Assets
8.73%
Debt
7.49%
Book Value per Share
10.39%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
6.46%
Shares Outstanding
13.94%
Long Term Trends
3Y Revenue/Share
424.28%
5Y Revenue/Share
46.46%
3Y Dividend/Share
46.65%
5Y Dividend/Share
29.07%